EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level

Wanda Phipatanakul, Nikolaos G Papadopoulos, Vivian Hernandez-Trujillo, Eckard Hamelmann, Robert S Zeiger, Francine M Ducharme, Changming Xia, Rebecca Gall, Olivier Ledanois, Amr Radwan, Juby A Jacob-Nara, Paul J Rowe und 1 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2026

DOI: 10.1016/j.jaip.2026.06.012 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Wanda Phipatanakul und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass. Elect…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Children with uncontrolled, moderate-to-severe asthma often have type 2 disease with allergic sensitization and/or elevated serum IgE. OBJECTIVE: To examine dupilumab efficacy in children aged 6 to 11 years with/without allergen sensitization. METHODS: In VOYAGE (NCT02948959), 408 children were randomized to receive dupilumab 100/200 mg every 2 weeks (by weight) or placebo for 52 weeks. This post hoc analysis included 336 children from VOYAGE with type 2 inflammation (eosinophils ≥150 cells/μL or fractional exhaled nitric oxide ≥20 ppb) and known baseline allergen sensitization status (based on total serum IgE and perennial allergen-specific IgE levels). The primary outcome assessed was annualized severe exacerbation rate; we also assessed change from baseline in pre- and postbronchodilator percent predicted forced expiratory volume in 1 second (ppFEV1), Interviewer-Administered 7-Item Asthma Control Questionnaire (ACQ-7-IA) score, and total and allergen-specific IgE levels. RESULTS: Of 336 children with type 2 inflammation and known baseline allergen sensitization status, 75 (22%) were nonsensitized, 58 (17%) monoallergen sensitized, and 203 (60%) multiallergen sensitized. Dupilumab versus placebo reduced asthma exacerbations by 45%, 75%, and 60% in the non-, mono-, and multisensitized subgroups (P = .1286, .0376, and .0004), respectively, by week 52, with no apparent interaction between treatment group and sensitization status (Pint = .48). Similar improvements were observed across sensitization subgroups for pre- and postbronchodilator ppFEV1, ACQ-7-IA, and total IgE levels. CONCLUSION: In children with type 2 asthma, dupilumab showed significant efficacy, reducing exacerbations and improving other outcomes in monoallergen- and multiallergen-sensitized patients, and numerical but nonsignificant effects in nonsensitized patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaChildFemaleHumansMaleAllergensDouble-Blind MethodImmunoglobulin ESeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Allergen sensitizationAllergic asthmaChildrenDupilumabExacerbationIgELung functionPediatricType 2 inflammationUncontrolled asthma

Substanzen

AllergensAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizeddupilumabImmunoglobulin E

Autor:innen und Institutionen

  • Department of Allergy and Immunology, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
  • Allergy Department, The 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece; Lydia Becker Institute, University of Manchester, Manchester, United Kingdom.
  • Allergy and Immunology Care Center of South Florida, Miami Lakes, Fla.
  • Bielefeld University, Bielefeld, Germany; Children's Center Bethel, University Hospital OWL, Bielefeld University, Bielefeld, Germany.
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, Calif.
  • Departments of Pediatrics and of Social and Preventive Medicine, University of Montreal, Montreal, QC, Canada.

Förderung

  • Regeneron Pharmaceuticals Inc
  • Sanofi US

Zitieren

APA

Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V., Hamelmann, E., Zeiger, R. S., Ducharme, F. M., Xia, C., Gall, R., Ledanois, O., Radwan, A., Jacob-Nara, J. A., Rowe, P. J., & Deniz, Y. (2026). Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.06.012

Vancouver

Phipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, Hamelmann E, Zeiger RS, Ducharme FM, et al. Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.06.012

BibTeX
@article{Phipatanakul2026,
  author = {Phipatanakul, Wanda and Papadopoulos, Nikolaos G and Hernandez-Trujillo, Vivian and Hamelmann, Eckard and Zeiger, Robert S and Ducharme, Francine M and Xia, Changming and Gall, Rebecca and Ledanois, Olivier and Radwan, Amr and Jacob-Nara, Juby A and Rowe, Paul J and Deniz, Yamo},
  title = {Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  doi = {10.1016/j.jaip.2026.06.012}
}
Kostenlos starten →